Payment overview · 2025
General Payments
$66.61
4 reported records · 4 companies
Healthcare provider profile · identity verified
Luna U Sy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OZARK, AL · NPI 1356455497
Verified facts
What the public records show
CMS Open Payments records show Luna U Sy, MD received $66.61 in general payments during 2025 across 4 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.24 | 28.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.51 | 26.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.18 | 24.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.68 | 20.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $66.61 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 64 |
| Losartan Potassium | Losartan Potassium | 214 | 55 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 180 | 55 |
| Simvastatin | Simvastatin | 170 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 49 |
| Potassium Chloride | Potassium Chloride | 146 | 43 |
| Omeprazole | Omeprazole | 145 | 37 |
| Ozempic | Semaglutide | 142 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 39 |
| Eliquis | Apixaban | 132 | 20 |
| Gabapentin | Gabapentin | 129 | 40 |
| Jardiance | Empagliflozin | 123 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 36 |
| Tramadol Hcl | Tramadol Hcl | 108 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 15 |
| Metformin Hcl Er | Metformin Hcl | 89 | 30 |
| Clonidine Hcl | Clonidine Hcl | 82 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 18 |
| Trazodone Hcl | Trazodone Hcl | 74 | 24 |
| Lisinopril | Lisinopril | 71 | 18 |
| Carvedilol | Carvedilol | 70 | 20 |
| Methylprednisolone | Methylprednisolone | 69 | 53 |
| Meloxicam | Meloxicam | 66 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 19 |
| Glimepiride | Glimepiride | 63 | 19 |
| Mounjaro | Tirzepatide | 63 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 28 |
| Allopurinol | Allopurinol | 61 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 15 |
| Fenofibrate | Fenofibrate | 54 | 19 |
| Celecoxib | Celecoxib | 53 | 16 |
| Metformin Hcl | Metformin Hcl | 53 | 16 |
| Atenolol | Atenolol | 50 | 12 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Furosemide | Furosemide | 49 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 14 |
| Irbesartan | Irbesartan | 47 | 15 |
| Montelukast Sodium | Montelukast Sodium | 47 | 13 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Mirtazapine | Mirtazapine | 43 | 14 |
| Nifedipine Er | Nifedipine | 43 | 14 |
| Bupropion Xl | Bupropion Hcl | 42 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 17 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 33 |
| Temazepam | Temazepam | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Valsartan | Valsartan | 37 | 13 |
| Bumetanide | Bumetanide | 36 | suppressed |
| Prednisone | Prednisone | 36 | 23 |
| Gemfibrozil | Gemfibrozil | 35 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Cefdinir | Cefdinir | 34 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 13 |
| Kerendia | Finerenone | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 14 |
| Topiramate | Topiramate | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 21 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Minoxidil | Minoxidil | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $66.61 · 4 records | Bayer Healthcare Pharmaceuticals Inc. | Auvelity, EVENITY, Kerendia, MOUNJARO, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error